Bayforest Capital Ltd Grows Stock Holdings in Lantheus Holdings, Inc. $LNTH

Bayforest Capital Ltd grew its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 258.5% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 11,152 shares of the medical equipment provider’s stock after purchasing an additional 8,041 shares during the period. Bayforest Capital Ltd’s holdings in Lantheus were worth $572,000 at the end of the most recent reporting period.

Several other institutional investors have also recently modified their holdings of LNTH. Elevation Point Wealth Partners LLC purchased a new position in shares of Lantheus during the 2nd quarter valued at about $26,000. Osterweis Capital Management Inc. bought a new position in Lantheus during the second quarter valued at approximately $36,000. Tripletail Wealth Management LLC purchased a new position in shares of Lantheus during the third quarter worth approximately $68,000. EverSource Wealth Advisors LLC lifted its holdings in shares of Lantheus by 190.2% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,065 shares of the medical equipment provider’s stock worth $87,000 after acquiring an additional 698 shares during the last quarter. Finally, EMC Capital Management bought a new stake in shares of Lantheus in the 2nd quarter worth approximately $93,000. 99.06% of the stock is currently owned by institutional investors.

Lantheus Stock Performance

Lantheus stock opened at $67.56 on Friday. The company has a current ratio of 2.67, a quick ratio of 2.49 and a debt-to-equity ratio of 0.51. The firm has a market cap of $4.48 billion, a P/E ratio of 28.39 and a beta of -0.11. Lantheus Holdings, Inc. has a 1-year low of $47.25 and a 1-year high of $111.29. The firm has a 50-day moving average of $61.15 and a 200-day moving average of $61.42.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings results on Tuesday, May 17th. The medical equipment provider reported $0.05 EPS for the quarter. The business had revenue of $92.51 million during the quarter. Lantheus had a return on equity of 30.88% and a net margin of 10.99%.Lantheus has set its FY 2025 guidance at 5.500-5.650 EPS. Sell-side analysts expect that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on LNTH shares. Weiss Ratings raised shares of Lantheus from a “sell (d+)” rating to a “hold (c-)” rating in a report on Tuesday. TD Cowen cut their price target on shares of Lantheus from $95.00 to $80.00 and set a “buy” rating for the company in a research report on Monday, September 15th. Mizuho lifted their price objective on Lantheus from $60.00 to $72.00 and gave the stock an “outperform” rating in a report on Wednesday, December 17th. The Goldman Sachs Group set a $77.00 target price on Lantheus and gave the company a “neutral” rating in a report on Wednesday, October 8th. Finally, Truist Financial raised their price target on Lantheus from $80.00 to $82.00 and gave the stock a “buy” rating in a research report on Thursday, December 18th. Five investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $78.00.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.